D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
Jasper van der Lugt,Reshma Saskia Autar,Sasiwimol Ubolyam,Evian Fernandez Garcia,Jongkol Sankote,Anchalee Avihingson,Theshinee Chuenyam,David A. Cooper,Joep M. A. Lange,Praphan Phanuphak,Ferdinand W. N. M. Wit,Kiat Ruxrungtham,David M. Burger +12 more
TL;DR: The pharmacokinetic parameters for the different treatment arms were adequate, however, the proportion of subjects with an undectable viral load at week 24 was lower than anticipated.
Journal ArticleDOI
The 2010 Royal Australasian College of Physicians' Policy Statement 'Circumcision of Infant Males' Is Not Evidence Based
Brian J. Morris,Alex Wodak,Adrian Mindel,Leslie Schrieber,K. A. Duggan,A. Dilley,Robin J. Willcourt,M. Lowy,David A. Cooper +8 more
TL;DR: The RACP's 2010 policy statement ‘Circumcision of infant males’ is analytically reviewed and it is found that the Statement is not a fair and balanced representation of the literature on MC.
Pathogenesis and management of HIV-associated drug hypersensitivity
Andrew Carr,David A. Cooper +1 more
Journal ArticleDOI
Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects.
Sean Emery,Cassy Workman,Rebekah Puls,Mark Bloch,David Baker,Neil J. Bodsworth,John Anderson,Suzanne M. Crowe,Martyn A. French,Jennifer F Hoy,Alexander C Aichelburg,Larry D. Ward,David B. Boyle,Matthew Law,Anthony D. Kelleher,David A. Cooper +15 more
TL;DR: Although safe, neither vaccine construct appeared to possess detectable T-cell mediated anti-HIV immunogenic properties in HIV infected individuals, as measured by standard T cell assays.
Journal ArticleDOI
Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy
Vijaya Madhavi,Fernanda Ana-Sosa-Batiz,Sinthujan Jegaskanda,Wendy R. Winnall,Matthew S. Parsons,Jintanat Ananworanich,David A. Cooper,Anthony D. Kelleher,Denise Hsu,Sarah Pett,Sarah Pett,Ivan Stratov,Marit Kramski,Stephen J. Kent +13 more
TL;DR: It is shown that cART resulted in significant reductions of HIV-specific effector antibody responses, including ADCC and ADP, which may be required to improve antibody-mediated control of HIV during cART.